import type { BlogArticle } from '../blog-types';

export const article: BlogArticle = {
  slug: "hexarelin-cardioprotection",
  title: "Hexarelin: Research on Cardiac and GH Applications",
  description:
    "A research overview of Hexarelin — a synthetic hexapeptide studied for growth hormone secretagogue activity and cardioprotective effects. What the published science shows.",
  category: "Compound Profiles",
  readMinutes: 10,
  publishedAt: "2026-06-18",
  ogImage: "/og-image.jpg",
  body: [
    {
      type: "paragraph",
      text: "Hexarelin (sequence: His-D-2-MeTrp-Ala-Trp-D-Phe-Lys-NH₂) is a synthetic hexapeptide and potent growth hormone secretagogue (GHS) developed in the early 1990s. It acts as an agonist at the GHS-R1a receptor (ghrelin receptor) and has been studied extensively for GH-releasing effects, hypothalamic-pituitary axis interactions, and — notably — a range of cardioprotective properties that appear to be at least partially independent of GH secretion.",
    },
    {
      type: "paragraph",
      text: "This latter finding has made Hexarelin one of the more scientifically interesting research peptides in cardiovascular pre-clinical research.",
    },
    {
      type: "heading",
      text: "Mechanism of Action",
    },
    {
      type: "subheading",
      text: "GHS-R1a Agonism",
    },
    {
      type: "paragraph",
      text: "Like other GHS compounds (Ipamorelin, GHRP-6, MK-677), Hexarelin binds to and activates the GHS-R1a receptor expressed in the pituitary, hypothalamus, and peripheral tissues. GHS-R1a activation in the pituitary triggers GH release; in peripheral tissues, it mediates several non-GH effects. Hexarelin is among the most potent GHS compounds studied, producing substantial GH release at relatively low concentrations in pre-clinical models. However, Hexarelin shows significant desensitization with continuous administration — a relevant consideration for research protocol design.",
    },
    {
      type: "subheading",
      text: "CD36 Receptor Binding",
    },
    {
      type: "paragraph",
      text: "A critical and distinguishing feature of Hexarelin research is its interaction with CD36 — a scavenger receptor expressed on cardiac myocytes, endothelial cells, and macrophages. CD36 has multiple roles: fatty acid uptake and utilization in cardiac tissue, oxidized LDL recognition (atherosclerosis relevance), and angiogenesis regulation.",
    },
    {
      type: "paragraph",
      text: "Hexarelin's binding to CD36 in cardiac tissue is thought to mediate its cardioprotective effects independently of GH or IGF-1 elevation. This was established in GH-deficient animal models where cardioprotective effects persisted despite negligible GH response.",
    },
    {
      type: "heading",
      text: "Growth Hormone Research Data",
    },
    {
      type: "subheading",
      text: "Comparison to Other GHSs",
    },
    {
      type: "paragraph",
      text: "In comparative studies examining GH-releasing potency: Hexarelin produces greater peak GH secretion than GHRP-6 and Ipamorelin in most rodent models. This potency advantage is partially offset by rapid desensitization — repeated Hexarelin administration leads to blunted GH response more rapidly than with Ipamorelin. Co-administration with GHRH analogs produces synergistic effects consistent with other GHS compounds.",
    },
    {
      type: "subheading",
      text: "Cortisol and Prolactin",
    },
    {
      type: "paragraph",
      text: "Unlike Ipamorelin, Hexarelin is not selective for GH at higher doses — it stimulates cortisol and prolactin secretion in a dose-dependent manner. This is an important consideration for research protocols where hormonal specificity is required.",
    },
    {
      type: "heading",
      text: "Cardioprotective Research",
    },
    {
      type: "subheading",
      text: "Ischemia-Reperfusion Injury",
    },
    {
      type: "paragraph",
      text: "Studies in isolated heart preparations and in vivo rodent models have documented that Hexarelin reduces ischemia-reperfusion (I/R) injury — the cell death and dysfunction that occurs when blood flow is restored after a period of ischemia.",
    },
    {
      type: "paragraph",
      text: "Locatelli et al. (1999) and subsequent work demonstrated that Hexarelin pre-treatment in rats reduced infarct size following coronary occlusion/reperfusion. Critically, these effects were present in hypophysectomized (GH-deficient) animals — confirming the mechanism is not GH-dependent — and were blocked by CD36 antagonism, confirming CD36 as the relevant mediator.",
    },
    {
      type: "subheading",
      text: "Cardiac Function in GH Deficiency",
    },
    {
      type: "paragraph",
      text: "GH-deficient patients and animal models consistently show impaired cardiac function — reduced cardiac output, increased vascular resistance, and altered cardiac morphology. Hexarelin treatment in GH-deficient models has shown improved cardiac output and ejection fraction, reduction in left ventricular hypertrophy in some models, and improved ventricular contractility documented in isolated heart preparations.",
    },
    {
      type: "paragraph",
      text: "Some of these effects are mediated via GH/IGF-1, while others (particularly contractility effects) appear to involve direct cardiac receptor activation.",
    },
    {
      type: "subheading",
      text: "Anti-Apoptotic Effects",
    },
    {
      type: "list",
      items: [
        "Reduced cardiomyocyte apoptosis following ischemic stress",
        "Upregulation of anti-apoptotic proteins (Bcl-2 family)",
        "Reduced cytochrome c release from mitochondria",
      ],
    },
    {
      type: "heading",
      text: "The CD36 Pathway: A Research Focus",
    },
    {
      type: "paragraph",
      text: "The identification of CD36 as a Hexarelin receptor in cardiac tissue opened a new dimension of GHS research. CD36 had been primarily studied in the context of lipid metabolism and atherosclerosis, but Hexarelin research has implicated it in cardioprotection signaling, anti-inflammatory effects in vascular tissue, and potential relevance to metabolic syndrome research (CD36 is involved in fatty acid uptake dysregulation in obesity).",
    },
    {
      type: "paragraph",
      text: "This makes Hexarelin not only a GHS research tool but also a pharmacological probe for CD36 function — a use case of independent scientific value.",
    },
    {
      type: "heading",
      text: "Research Protocol Considerations",
    },
    {
      type: "list",
      items: [
        "Solubility: Water-soluble; reconstitute in bacteriostatic water",
        "Stability in solution: Store at 2–8°C; use within 4 weeks",
        "Desensitization: Significant with continuous administration; intermittent protocols recommended",
        "GH selectivity: Less selective than Ipamorelin; monitor cortisol/prolactin in GH-focused protocols",
        "Purity requirement: HPLC ≥98%; mass spec identity confirmation essential",
      ],
    },
    {
      type: "heading",
      text: "Summary",
    },
    {
      type: "paragraph",
      text: "Hexarelin occupies a unique position in GHS research: it is among the most potent GH-releasing peptides studied, while simultaneously demonstrating cardioprotective effects through a GH-independent CD36-mediated pathway. The ischemia-reperfusion protection data is well-replicated in animal models, and the CD36 mechanism is mechanistically characterized. Its lower GH selectivity compared to Ipamorelin and its rapid desensitization profile are relevant practical considerations for research design.",
    },
    {
      type: "callout",
      text: "For research purposes only. Not intended for human use.",
    },
  ],
};
